12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NEOD001: Phase I started

Prothena began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV NEOD001 every 28 days in about 50 patients. The product...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >